HeartSciences to Present at the LD Micro Invitational XIV Conference
Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be RecommendedSouthlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a
Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 Loss per Share (Vs US$0.16 Loss in 3Q 2023)
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients With Type 2 Diabetes
Southlake, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical
HeartSciences Adds Key Advisor to Its Scientific Advisory Board
HeartSciences Expands Its Scientific Advisory Board
Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered m
HeartSciences Appoints New Scientific Advisory Board Member
Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered m
HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
Southlake, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), would like to remind its shareholders to
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
Southlake, TX, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
Southlake, TX, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences Announces Closing of License Agreements With the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
Southlake, TX, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered m
HeartSciences' MyoVista WavECGTM Selected for Heart Screening of Irish Garda National Police Officers
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an AI-powered medical technology company focused on
HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments
Entered into Transformative Agreements with Icahn Mount Sinai Filed FDA Pre-Submission Request to Change to 510(k) Submission from De Novo following Issuance of New Classification for AI ECG by FDA To host
HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I.
Southlake, TX, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based me
HeartSciences Reports First Quarter Fiscal 2024 Financial Results
Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based
HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase
Southlake, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based
HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards
Southlake, TX, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based
HeartSciences Signs Distribution Agreement With MedPhy Technologies, Mumbai, India
Southlake, TX, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based me
No Data